Financial Performance - Unaudited U.S. net product sales revenue of IBSRELA (tenapanor) for Q4 2024 was approximately $54 million, and approximately $158 million for the full year 2024[8] - Unaudited U.S. net product sales revenue of XPHOZAH (tenapanor) for Q4 2024 was approximately $57 million, and approximately $161 million for the full year 2024[8] - As of December 31, 2024, the company had cash, cash equivalents, and short-term investments of approximately $250 million[3] Financial Data Disclosure - The preliminary financial data is subject to adjustment and may differ materially in the audited financial statements[4] - The preliminary financial data is the responsibility of the company's management and has not been audited or reviewed by Ernst & Young LLP[5]

Core Insights - Ardelyx, Inc. reported significant commercial progress in 2024, achieving total revenue of $333.6 million, with U.S. net product sales of $319.2 million [1][7] - The company reaffirms combined peak sales expectations for IBSRELA and XPHOZAH at $1.75 billion [1] - Ardelyx ended FY 2024 with a strong cash position of $250.1 million [1][7] Financial Performance - Total revenue for 2024 was $333.6 million, a substantial increase from $124.5 million in 2023, primarily driven by net product sales [7] - IBSRELA's U.S. net product sales revenue reached $158.3 million in 2024, up from $80.1 million in 2023 [4][7] - XPHOZAH generated $160.9 million in U.S. net product sales revenue in its first full year of commercialization, compared to $2.5 million in 2023 [5][7] - The company reported a net loss of $39.1 million for 2024, an improvement from a net loss of $66.1 million in 2023 [13][7] Product Sales and Market Expectations - IBSRELA is expected to achieve U.S. net product sales revenue between $240 million and $250 million in 2025, with a projected peak market share of over 10% [4] - XPHOZAH is anticipated to reach $750 million in annual U.S. net product sales revenue at peak [5] Corporate Developments - Ardelyx released its 2024 Environmental, Social and Governance (ESG) report, highlighting its commitment to sustainability [6] - The company is focused on growing IBSRELA, executing the XPHOZAH strategy, and building a pipeline of important medicines [3]

WALTHAM, Mass., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that management will present at TD Cowen’s 45th Annual Health Care Conference on Monday, March 3, 2025 at 9:50am ET in Boston. To access the live webcast of the panel presentation please visit the Events and Presentations page within the Ardelyx ...

WALTHAM, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced it will hold a conference call on Thursday, February 20, 2025, at 8:00 a.m. Eastern Time to discuss financial results and provide a business update from the full year and fourth quarter of 2024. To participate in the conference call, please dial ( ...

Ardelyx (ARDX) shares soared 16% in the last trading session to close at $5.88. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 2.9% loss over the past four weeks.The stock rallied after the company announced preliminary total U.S. net product sales of $319 million in 2024, backed by growing demand for its two drugs, Ibsrela and Xphozah. Ibsrela sales in the fourth quarter of 2024 are expected to be $54 million, bringing the full ...

Company achieved significant commercial progress in 2024, finishing with total U.S. net product sales revenue of approximately $319 million (unaudited) Company reaffirms peak U.S. net IBSRELA sales revenue of greater than $1 Billion Company announces peak U.S. net XPHOZAH sales revenue of $750 million Company finishes 2024 with approximately $250 million in cash, cash equivalents and investments (unaudited) WALTHAM, Mass., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical c ...

WALTHAM, Mass., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that Mike Raab, President and CEO, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025 at 4:30pm PT in San Francisco. To access the live webcast of the panel presentation please visit the Events and Pr ...

Ardelyx (NASDAQ: ARDX ) lost the lawsuit against Medicare, the one that I was worried about in my earlier article . With that loss, XPHOZAH faces the prospect of much reduced and declining revenue. ARDX has no other major prospectAbout the TPT serviceThanks for reading. At the Total Pharma Tracker, we offer the following:-Our Android app and website features a set of tools for DIY investors, including a work-in-progress software where you can enter any ticker and get extensive curated research material. For ...

WALTHAM, Mass., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that Justin Renz, Chief Financial and Operations Officer, and Eric Foster, Chief Commercial Officer, will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference on Wednesday, December 4, 2024 at 12:30pm EST in New Y ...

I'm an investment analyst with clinical experience in healthcare and an MBA, expanding my focus from biotech to a range of sectors. I've had the privilege of sharing my insights on Seeking Alpha since 2017, emphasizing financial modeling techniques like DCF analysis to identify underlying assumptions in stock valuations. I provide scenario-based forecasts to help readers gauge reasonable outcomes. Influenced by works like Superforecasting and Antifragile, I advocate for disciplined risk management through a ...